Juntendo Medical Journal
Online ISSN : 2188-2126
Print ISSN : 2187-9737
ISSN-L : 2187-9737
Special Reviews: 348th Triannual Meeting of the Juntendo Medical Society “Medical Research Update”
Development of Immunotherapy and Targeted Therapy for Non-small-cell Lung Cancer at the Ohio State University
Author information

2020 Volume 66 Issue 3 Pages 194-199


 After working as a medical doctor specializing in respiratory medicine for 13 years and performing mainly clinical studies and some translational research during graduate courses, I wanted to perform basic science research during postdoctoral training in the USA. I worked as a postdoctoral fellow in Dr. David Paul Carbone’s laboratory from May 2015 to January 2019. Dr. Carbone is one of the leading physician scientists who was an erstwhile president of the International Association for the Study of Lung Cancer (IASLC). In his lab, basic and translational studies are conducted to improve the outcome of the patients with advanced thoracic malignancies. Professor Takahashi, who is the head of the Department of Respiratory Medicine at Juntendo University, supported me in my postgraduate training in Dr. Carbone’s lab.

 In this article, I have summarized the studies that I did with Dr. Carbone. I have written and published one review article titled “Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer,” one case report titled “Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy, ”and two research articles titled “Surrogate endpoints for overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy” and “The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.”

Information related to the author
© 2020 The Juntendo Medical Society. This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original source is properly credited.

This article is licensed under a Creative Commons [Attribution 4.0 International] license.
Previous article Next article